SEHK:6990
SEHK:6990Biotechs

A Look At Sichuan Kelun Biotech (SEHK:6990) Valuation After New Breakthrough Therapy And IND Approvals

Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) has drawn fresh investor attention after China’s regulator granted Breakthrough Therapy Designation for sacituzumab tirumotecan with pembrolizumab in first line PD-L1-positive lung cancer, alongside IND approval for SKB105 in advanced solid tumors. See our latest analysis for Sichuan Kelun-Biotech Biopharmaceutical. The latest regulatory milestones appear to be feeding into strong momentum, with a 1-day share price return of 2.64%, a 7-day...
SEHK:2259
SEHK:2259Metals and Mining

Asian Value Stocks Trading Below Estimated Worth In January 2026

As we enter 2026, Asian markets are capturing global attention with their robust performance, driven by optimism in the tech sector and a resurgence in consumer spending. Amidst this momentum, investors are increasingly looking for value stocks—those trading below their estimated worth—that could offer potential opportunities within this thriving economic landscape.
SEHK:6090
SEHK:6090Personal Products

Uncovering Undiscovered Gems In Asia January 2026

As we enter 2026, the Asian markets are capturing global attention with strong performances, particularly in the small-cap segment, echoing trends seen in other regions where small-cap and value shares have outpaced their larger counterparts. In this dynamic environment, identifying promising stocks involves looking for those with solid fundamentals and growth potential that can thrive amid current economic indicators and evolving market sentiments.
SEHK:9959
SEHK:9959Software

Asian Penny Stocks To Watch In January 2026

As we enter January 2026, Asian markets are experiencing a notable upswing, with equities advancing and indices reaching new heights amid global optimism. In this context, penny stocks—typically representing smaller or newer companies—continue to capture investor interest due to their potential for growth at lower price points. While the term "penny stocks" may seem outdated, these investments can still offer value when supported by strong financials and solid fundamentals, presenting an...
SEHK:2616
SEHK:2616Biotechs

Is CStone Pharmaceuticals (SEHK:2616) Turning Sugemalimab Data Into a Sustainable Immuno-Oncology Edge?

EQRx, based in Cambridge, USA, previously reported new clinical trial data for its lung cancer candidate sugemalimab, a monoclonal antibody developed in collaboration with CStone Pharmaceuticals, with plans to present the findings at the World Conference on Lung Cancer 2021. The therapy’s design to mirror a naturally occurring antibody, potentially lowering immunogenicity and toxicities, highlights CStone’s exposure to differentiated immuno-oncology innovation through this partnership. We’ll...
SEHK:3330
SEHK:3330Metals and Mining

Assessing Lingbao Gold Group (SEHK:3330) Valuation After Upgraded 2025 Earnings Guidance

Lingbao Gold Group (SEHK:3330) has issued new full year 2025 earnings guidance, indicating higher revenue and a much larger net profit range, supported by increased gold output, efficiency gains and favorable gold prices. See our latest analysis for Lingbao Gold Group. The guidance arrives after a sharp run in Lingbao Gold Group’s shares, with a 1-month share price return of 15.14% and a very large 1-year total shareholder return, suggesting that momentum has been building as investors...
SEHK:2155
SEHK:2155Machinery

Assessing Morimatsu International Holdings (SEHK:2155) Valuation After Board Non Compliance Update

Morimatsu International Holdings (SEHK:2155) has reported the death of independent non executive director Mr. Kanno Shinichiro, leaving the company temporarily out of compliance with several Hong Kong Stock Exchange board composition rules. See our latest analysis for Morimatsu International Holdings. The news comes after a strong run in the shares, with the latest share price at HK$10.9 and a 30 day share price return of 25.58%. The 1 year total shareholder return of 162.87% signals powerful...
SEHK:336
SEHK:336Chemicals

Assessing Huabao International Holdings (SEHK:336) Valuation After The Recent CEO Transition

Huabao International Holdings (SEHK:336) is back in focus after the board announced a CEO transition, with long serving leader Ms. Chu Lam Yiu stepping down from the role and Mr. Xia Liqun taking over. See our latest analysis for Huabao International Holdings. The CEO handover comes after a period of strong short term momentum, with the 7 day share price return of 11.53% and 90 day share price return of 18.67%. However, the 1 year total shareholder return of 122.44% contrasts with a far...
SEHK:6618
SEHK:6618Consumer Retailing

A Look At JD Health International’s Valuation After Analyst Optimism And Strong Quarterly Earnings

JD Health International (SEHK:6618) has drawn fresh attention after favorable analyst commentary coincided with quarterly results showing year-on-year revenue and profit growth, prompting investors to reassess the online healthcare platform’s recent share performance. See our latest analysis for JD Health International. The recent 5.01% 1 day share price return and 15.21% 7 day share price return suggest momentum has picked up again, although the 143.38% 1 year total shareholder return...
SEHK:700
SEHK:700Interactive Media and Services

Tencent Holdings (SEHK:700) Valuation Check As New AI Leadership And WeChat Integration Take Shape

Tencent Holdings (SEHK:700) is back in focus after recruiting former OpenAI scientist Yao Shunyu to lead its artificial intelligence push, as the company links its Yuanbao assistant with WeChat chat history for more tailored services. See our latest analysis for Tencent Holdings. The HK$623.0 share price sits against a 1-year total shareholder return of 71.7% and a 3-year total shareholder return of 72.4%. This suggests recent AI announcements are feeding into already strong longer term...